Log in here:
Forgot your password?
This review discusses the evidence in support of the use of macitentan (Opsumit®), a novel dual endothelin receptor antagonist (ERA), in the treatment of pulmonary arterial hypertension (PAH).
Subscribe
Ctrl + 1 Home
Ctrl + 2 A-Z Guide
Ctrl + 3 Expert Writers
Ctrl + 4 Sign Up here
Ctrl + 5 About Us
Ctrl + 6 Contact Us
? Help